Nasdaq Absi News Today

Absci Co. (NASDAQ:ABSI – Free Report) – HC Wainwright increased their FY2025 earnings estimates for shares of Absci in a report released on Monday, January 8th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.23) per share for the year, up from their previous estimate of ($0.30). HC Wainwright […]

KeyCorp initiated coverage on shares of Absci (NASDAQ:ABSI – Free Report) in a research note published on Tuesday morning, Marketbeat reports. The firm issued an overweight rating and a $3.00 price target on the stock. KeyCorp also issued estimates for Absci’s Q4 2023 earnings at ($0.22) EPS, FY2023 earnings at ($1.17) EPS and FY2024 earnings […]

Casdin Capital LLC cut its holdings in shares of Absci Co. (NASDAQ:ABSI – Free Report) by 74.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,368,260 shares of the company’s stock after selling 4,025,000 shares during the period. Casdin Capital […]

Absci Co. (NASDAQ:ABSI – Get Free Report) was the recipient of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 2,300,000 shares, a decline of 6.5% from the October 31st total of 2,460,000 shares. Based on an average daily volume of 323,400 shares, the […]

Platinum Investment Management Ltd. increased its stake in Absci Co. (NASDAQ:ABSI – Free Report) by 124.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,306,668 shares of the company’s stock after buying an additional 725,144 shares during the quarter. […]

HC Wainwright reaffirmed their buy rating on shares of Absci (NASDAQ:ABSI – Free Report) in a report released on Wednesday morning, MarketBeat reports. The brokerage currently has a $4.00 price target on the stock. HC Wainwright also issued estimates for Absci’s Q4 2023 earnings at ($0.21) EPS, Q2 2024 earnings at ($0.17) EPS, Q3 2024 […]

The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases...

Wealth Alliance Advisory Group LLC acquired a new stake in Absci Co. (NASDAQ:ABSI – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 28,240 shares of the company’s stock, valued at approximately $43,000. Other hedge funds and other institutional investors have also added to or […]

Absci (NASDAQ:ABSI – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Truist Financial in a report released on Wednesday, Benzinga reports. They presently have a $10.00 target price on the stock. Separately, HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Absci in a […]

Entered into partnership with Google Ventures-backed biotech company to discover innovative new medicines Entered into collaboration with Caltech,...